Isoform Positions

Isoform Protein Position Transcript Position Chromosomal Position (HG38) Chromosomal Position (HG19)
IC2801784274;84275;84276 chr2:178562083;178562082;178562081chr2:179426810;179426809;179426808
N2AB2637679351;79352;79353 chr2:178562083;178562082;178562081chr2:179426810;179426809;179426808
N2A2544976570;76571;76572 chr2:178562083;178562082;178562081chr2:179426810;179426809;179426808
N2B1895257079;57080;57081 chr2:178562083;178562082;178562081chr2:179426810;179426809;179426808
Novex-11907757454;57455;57456 chr2:178562083;178562082;178562081chr2:179426810;179426809;179426808
Novex-21914457655;57656;57657 chr2:178562083;178562082;178562081chr2:179426810;179426809;179426808
Novex-3NoneNone chr2:Nonechr2:None

Information

  • RefSeq wild type amino acid: V
  • RefSeq wild type transcript codon: GTA
  • RefSeq wild type template codon: CAT
  • Domain: Ig-142
  • Domain position: 55
  • Structural Position: 135
  • Q(SASA): 0.2185
  • Predicted PPI site: N

Reported SAVs

SNV RS
DUET
PolyPhen-2
Condel
Rhapsody
REVEL
MVP
Source
MAF
Disease
Zygosity
Site annotation
mCSM PPI
Predicted PPI site
Comments
AFR
AMR
AMS
ASJ
EAS
EUR
FIN
MDE
NFE
SAS
OTH
V/I rs777711368 -0.36 0.166 N 0.343 0.08 0.510872562601 gnomAD-2.1.1 4.06E-06 None None None None N None 0 0 None 0 0 None 0 None 0 8.99E-06 0
V/I rs777711368 -0.36 0.166 N 0.343 0.08 0.510872562601 gnomAD-4.0.0 3.18518E-06 None None None None N None 0 0 None 0 0 None 0 0 2.85997E-06 1.43406E-05 0

Saturation Mutagenesis

SAV
AlphaMissense (IC)
AlphaMissense Class (IC)
AlphaMissense (N2AB)
AlphaMissense Class (N2AB)
mCSM
mCSM class
PolyPhen-2
PolyPhen-2 Class
Rhapsody
Rhapsody Class
Condel
Condel Score
Site annotation
mCSM PPI
Predicted PPI site
V/A 0.1132 likely_benign 0.1267 benign -1.379 Destabilizing 0.08 N 0.246 neutral N 0.474240527 None None N
V/C 0.5051 ambiguous 0.5349 ambiguous -1.257 Destabilizing 0.965 D 0.52 neutral None None None None N
V/D 0.2784 likely_benign 0.3 benign -1.021 Destabilizing 0.561 D 0.616 neutral None None None None N
V/E 0.2028 likely_benign 0.2237 benign -1.034 Destabilizing 0.491 N 0.57 neutral N 0.449496798 None None N
V/F 0.1042 likely_benign 0.1179 benign -1.279 Destabilizing 0.561 D 0.568 neutral None None None None N
V/G 0.1697 likely_benign 0.1825 benign -1.651 Destabilizing 0.166 N 0.557 neutral N 0.443418975 None None N
V/H 0.3155 likely_benign 0.3538 ambiguous -1.177 Destabilizing 0.965 D 0.583 neutral None None None None N
V/I 0.0714 likely_benign 0.07 benign -0.745 Destabilizing 0.166 N 0.343 neutral N 0.45782828 None None N
V/K 0.2447 likely_benign 0.2778 benign -0.945 Destabilizing 0.561 D 0.575 neutral None None None None N
V/L 0.1209 likely_benign 0.1319 benign -0.745 Destabilizing None N 0.117 neutral N 0.406074095 None None N
V/M 0.0848 likely_benign 0.0891 benign -0.692 Destabilizing 0.818 D 0.446 neutral None None None None N
V/N 0.1627 likely_benign 0.1659 benign -0.809 Destabilizing 0.561 D 0.609 neutral None None None None N
V/P 0.8883 likely_pathogenic 0.8981 pathogenic -0.922 Destabilizing 0.722 D 0.603 neutral None None None None N
V/Q 0.1973 likely_benign 0.223 benign -1.014 Destabilizing 0.818 D 0.604 neutral None None None None N
V/R 0.2192 likely_benign 0.2564 benign -0.498 Destabilizing 0.561 D 0.627 neutral None None None None N
V/S 0.1154 likely_benign 0.1226 benign -1.391 Destabilizing 0.002 N 0.287 neutral None None None None N
V/T 0.1013 likely_benign 0.1067 benign -1.292 Destabilizing 0.007 N 0.121 neutral None None None None N
V/W 0.6064 likely_pathogenic 0.6716 pathogenic -1.388 Destabilizing 0.991 D 0.593 neutral None None None None N
V/Y 0.318 likely_benign 0.3522 ambiguous -1.063 Destabilizing 0.901 D 0.541 neutral None None None None N

Titin has multiple isoforms, the longest being the theoretical IC (inferred complete) isoform which contains all 363 in-frame titin exons. Here all isoform positions have been mapped onto the IC sequence, with an exception being the C-terminal of the much shorter novex-3 isoform. This contains the out of frame exon 48 which cannot be mapped to the other isoforms.